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Estimating protein intake
in maintenance
hemodialysis patients
To the Editor: We have read with interest the paper in
a recent issue of Kidney International by Masud et al [1]
on the precision of estimating the protein intake in chronic
renal failure (CRF). The authors provide evidence that
the amount of protein intake does not reflect the excretion
of fecal nitrogen; thus, fecal nitrogen, even if correlated
with body weight, does not influence the measurement
of protein intake in stable CRF patients. The accurate
estimation of protein intake is even more crucial in hemo-
dialysis (HD) patients because of the greater risk of mal-
nutrition. In clinical practice, protein intake is usually
estimated in HD by the calculation of protein nitrogen
appearance (PNA) derived from the urea nitrogen ap-
pearance (UNA) during the interdialytic period [2]. To
note, the effect of fecal nitrogen excretion on the mea-
surement of protein intake and the influence of different
amount of eaten protein on the fecal excretion of nitro-
gen, as well, have not been previously evaluated.
We analyzed 139 series of three-day period daily pro-
tein intakes measured during the long interdialytic inter-
val. The mean interdialytic protein intake estimated by
PNA was 1.26  0.28 g/kg body weight/day (range, 0.66
to 2.18), while the daily protein intake progressively de-
creased from 1.50  0.43 to 1.32  0.35 and to 1.00 
0.34 g/kg body weight/day (P  0.001) during the three-
day period (range, 0.71 to 2.91, 0.49 to 2.29, and 0.22 to
1.82, respectively, on the 1st, 2nd, and 3rd day). Twenty-
seven patients (age, 32 to 70 years; body weight, 52 to
78 kg) collected the daily feces during the same time
period in order to measure the fecal nitrogen excretion.
At variance with UNA, which gradually dropped, fecal
nitrogen (FN) remained unchanged during the interdia-
lytic period (Fig. 1). Fecal nitrogen excretion was remark-
ably stable during the study, measuring 5.0 mg/kg body
weight/day (range, 4.0 to 6.6) on each of the 3 days (NS);
the coefficient of variation was lower than 3% (range,
0.5 to 4.0).
In HD patients, variations of eaten protein do not
affect the fecal excretion of nitrogen; therefore, in these
patients, as demonstrated in CRF [1], fecal nitrogen does
not influence the measurement of protein intake.
Fig. 1. Daily measurement of urea nitrogen appearance (UNA) ()
and fecal nitrogen excretion (FN) ( ) in chronic hemodialysis patients
during the long interdialytic period. *P  0.05 vs. 1; P  0.05 vs. 2.
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Plasma level of soluble Fas is
an independent marker of
cardiovascular disease in
ESRD patients
To the Editor: In the October 2002 issue of Kidney
International, Caglar K et al [1] discussed the potential
inflammatory role of hemodialysis (HD) in end-stage re-
nal disease (ESRD) patients. Evidence suggests that apo-
ptotic endothelial cells are present at sites of atherosclero-
sis plaques [2]. To evaluate the association between
inflammation, endothelial apoptosis, and cardiovascular
(CV) morbidity and mortality in ESRD patients, we have
measured plasma level of soluble Fas (sFas) was measured
by enzyme-linked immunosorbent assay (ELISA) in a
cross-sectional analysis [3]. Eighteen chronic HD patients,
9 non-HD ESRD patients (CrCl, 10.3 2.4 mL/min), and
15 age- and sex-matched healthy subjects (CrCl, 98.4 3.5
